Friday, July 26, 2024 5:08:00 AM
Of course Kings Health Partnership / Kings College Hospital / Professor Ashkan have an ongoing commercial interest with NWBO,
The clue was in the 'Commercial Partnership Agreement' signed by all parties.
With the main driver, being the fact that there would be a ready supply of recently diagnosed GBM4 patients, with which to sell the 'vaccine' to.
This aspect of that understanding is in full operation to this day.
Now, it is a fact that ALL vested interests in this UK supply chain model, with benefit substantially from a MAA grant. That is the nature of the clinical trial business.
And if it all goes to plan, that return will increase again, when DIRECT is pushed to the front by the same players in due course.
It is NO different to why all of you are investing your time and capital in NWBO. It is to make MONEY off and from a patient's misfortune.
The clue was in the 'Commercial Partnership Agreement' signed by all parties.
With the main driver, being the fact that there would be a ready supply of recently diagnosed GBM4 patients, with which to sell the 'vaccine' to.
This aspect of that understanding is in full operation to this day.
Now, it is a fact that ALL vested interests in this UK supply chain model, with benefit substantially from a MAA grant. That is the nature of the clinical trial business.
And if it all goes to plan, that return will increase again, when DIRECT is pushed to the front by the same players in due course.
It is NO different to why all of you are investing your time and capital in NWBO. It is to make MONEY off and from a patient's misfortune.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
